Verts Neighborhood Dispensary expanded its brand into Missouri and Michigan including four new locations in Missouri and a location in the Upper Peninsula and western side of Michigan.
…
HOUSTON – October 25, 2022 – (Newswire.com)
CRITERION ENERGY PARTN…
Sunshine plans an aggressive clinic opening schedule in rural and suburban areas along with franchising. Sunshine Care Virtual Clinics and SunshineCare.Online are companies created from the result of prior ObamaCare In…
Virtual workshop on Nov. 17-18 bridges the gap between critical stakeholders to pinpoint today’s challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.
MINNEAPOLIS – October 24, 2022 – (Newswire.com)
The AcCELLerate Forum, a joint partnership between the American Society for Transplantation and Cellular Therapy (ASTCT™), the Center for International Blood and Marrow Transplant Research® (CIBMTR®), and the National Marrow Donor Program® (NMDP)/Be The Match®, brings key stakeholders together to identify ongoing needs and opportunities in cell and gene therapy for advocacy, measurement of value and impact and sustainability. The virtual workshop on Nov. 17-18, 2022, joins providers, payers, government agencies and industry members who will work together to define essential factors needed to create a sustainable cell and gene therapy ecosystem.
“NMDP/Be The Match is proud to be one of the sponsors of this important forum that has interests for all key stakeholders across the ecosystem,” said Jeffery Auletta, M.D., Senior Vice President, Patient Outcomes and Experience, of NMDP/Be The Match, Chief Scientific Director, CIBMTR. “Our established relationships with a global network of transplant centers and cell and gene therapy developers uniquely position NMDP/Be The Match to bring these experts together to identify the needs and opportunities in this field for advocacy, measurement, and sustainability.”
Dr. Auletta will join industry and transplant center partners and other professionals to address the question, “Are Center-Specific Outcomes Possible for CAR T-cell Immunotherapy?” The participants will focus on the perspectives of the payer, data acquisition and analysis, and center perspectives in defining outcomes for CAR T cells. They will also discuss healthcare inequity, specifically barriers to access and their impact on cell therapy outcomes. The speakers will incorporate the evolving cell therapy landscape from industry collaboration to clinical trials and real-world treatment in their presentations and in a moderator-led roundtable with attendee participation. Visit the event website to register and see the complete schedule and list of presenters.
In addition to NMDP/Be The Match, the event co-hosts include:
The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. For more information about ASTCT, visit www.astct.org and follow us on Twitter, @ASTCT.
The CIBMTR, a research collaboration between the NMDP/Be The Match and the Medical College of Wisconsin, facilitates critical cellular therapy research through a clinical database of more than 600,000 patients from more than 350 centers worldwide, with a biospecimen repository of more than 195,000 samples.
Background:
The National Marrow Donor Program® (NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With 35 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®—a collaboration with the Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care.
Contact Information:
Phyllis Grabot
Bonnie Quintanilla
Press Release Service
by
Newswire.com
Original Source:
The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy
MensWeddingBands.io Features Top-Tier Wedding Bands That are Easily Searched by Price or Material
IVINS, Utah – October 24, 2022 – (Newswire.com)
Tayloright LLC, a top-tier online store for classic men’s wedding rings, is in the news again today for launching a new website. The company is excited to announce the launch of its new website to the public on www.mensweddingbands.io. The men’s wedding ring brand has been operating for the past 10 years and has been in the men’s wedding band industry for over 23 years.
Tayloright is expanding its business, and the company’s latest website has more features that accommodate its new set of operations. The new website features a column for tungsten, titanium, wood, damascus steel, dinosaur bone, carbon fiber, ceramic, antler, and meteorite men’s wedding bands. There is also a “home section” where shoppers and existing customers can see various types of men’s wedding bands for sale.
Here are bullet points that highlight the main sections shoppers can find on the new Tayloright LLC website (www.mensweddingbands.io):
This section summarizes why shoppers should purchase their men’s wedding bands from Tayloright LLC. The company promises to deliver quality-crafted rings at affordable prices. The brand also has a reliable customer care service that is constantly available to take care of shoppers’ needs.
Under this section, Tayloright LLC also promises fast delivery to their customers — they do same-day delivery. The company also states that there is an option for shoppers to pick up their order if they stay close to Tayloright LLC’s physical location in New York.
No wedding bands will last without maintenance. Although wedding bands from Tayloright LLC are durable and sturdy, they still require a certain level of care to keep them in good shape to last longer. This section of the website provides some tips on how shoppers can maintain their wedding rings after purchase.
This section covers some questions customers or new shoppers might ask when they visit the new website.
This part of the new website contains blog posts and news about the brand. All the articles and content that have to do with Tayloright LLC are there.
“With joy in our hearts, Tayloright LLC is announcing the launch of our latest online store, developed with our customers in mind,” said Taylor Johnson, the CEO and founder of Tayloright LLC. “Our previous websites are still up and running, but we are expanding our services, which has increased the need for another website. The latest website will contain most of our new line of men’s wedding bands.”
Contact Information:
Taylor Johnson
CEO
435-275-9057
Press Release Service
by
Newswire.com
Original Source:
Tayloright, Premier Online Store for Classic Men’s Wedding Bands, Launches New Website, Featuring a Ring for Every Man, Regardless of Personality
The leading provider of court data workflow automation in the U.S. elevates security in the midst of state court expansion.
PacerPro SOC 2 Complian…
Recent Project: Robotic Sorting Facility
SOUTH BEND, Ind. – October 24, 2022 – (Newswire.com)
…
Bitcoin, Ethereum, and other cryptocurrencies are now being closely tracked by HackerNoon through Coin Pages powered by CoinMarketCap. Readers can view these pages to see daily changes in each coin’s price and market cap alongside recently published stories.
EDWARDS, Colo. – October 24, 2022 – (Newswire.com)
HackerNoon, a website focused on publishing stories about technology, has launched new coin pages to track popular cryptocurrencies such as Bitcoin and Ethereum. The coin data is constantly updated, tracking changes in each currency over a period of 24 hours.
“As the crypto space is evolving, so is HackerNoon,” wrote CEO David Smooke in an article announcing these new pages. “Our next step is to give our readers and writers better data within our technology publishing platform.”
By default, the list of coin pages is ranked according to market cap. “Too much of the crypto and mainstream media talk about Bitcoin breaking $10k, $20k, $50k,” wrote David, “but in reality, what they should be talking about is the market cap. This simple but important distinction is missed by most mainstream media.” Coins ranked at the top currently include Bitcoin, Ethereum, and XRP. Viewers can also sort this list by price and price change, as well as alphabetical order.
The prices are tracked in collaboration with CoinMarketCap. Through combining their information with HackerNoon’s own engineering, each page contains a graph tracking changes in a currency’s price over time. These pages also provide information on each currency’s trading volume and circulating supply, giving readers the chance to see how each coin’s popularity has changed over time.
Coin pages will also help distribute stories written by HackerNoon contributors. Each currency on the list of pages is paired with the latest article that includes that currency as a topic. When viewing a page, it’s also possible to see a curated list of HackerNoon stories alongside stories from other websites surrounding the chosen coin. HackerNoon offers these stories as a way to help readers and hodlers keep track of trending topics in relation to various cryptocurrencies.
In the future, HackerNoon hopes to add detailed descriptions to every currency on the list, providing information on each coin’s history and milestones. Nearly every page contains a short description; more popular currencies have entire paragraphs detailing their criticisms and claims to fame.
“We’re concentrating on integrating more API-driven data sources about companies, cryptocurrencies, software and people,” wrote David. “These coin price pages will be a quantitative and qualitative destination to learn more about what’s happening with every top cryptocurrency.”
About HackerNoon
HackerNoon is built for technologists to read, write, and publish. We are an international community of 30,000+ contributing writers and 4,000,000+ curious and insightful monthly readers. Get your technology story published today.
Contact Here | Email
Visit us on social media:
Facebook | Twitter | LinkedIn
Contact Information:
Limarc Ambalina
VP of Editorial
Press Release Service
by
Newswire.com
Original Source:
HackerNoon Introduces Coin Pages in Collaboration With CoinMarketCap to Track the Prices and Popularity of the Internet’s Biggest Cryptocurrencies
Emergency Planning Professional Emergency Planning Professional Banner
CHICAGO – October 24, 2022 – (Newswire.com)…
Gb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.
LAS VEGAS – October 24, 2022 – (Newswire.com)
Gb Sciences, Inc. (“GbS”; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS’ proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS’ proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company’s first non-cannabis formulations to advance in preclinical studies.
“We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations,” said Dr. Andrea Small-Howard, Gb Sciences’ President and Chief Science Officer. “This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs.”
For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.
The PhAROSTM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines.
To learn more about Gb Sciences, visit www.gbsciences.com.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Media Contact
Alexis Quintal
Contact Information:
Madeleine Moench
Press Release Service
by
Newswire.com
Original Source:
Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
